MedCap Past Earnings Performance
Past criteria checks 5/6
MedCap has been growing earnings at an average annual rate of 32%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 17.3% per year. MedCap's return on equity is 18.6%, and it has net margins of 12.1%.
Key information
32.0%
Earnings growth rate
30.3%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 17.3% |
| Return on equity | 18.6% |
| Net Margin | 12.1% |
| Next Earnings Update | 13 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MedCap makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,679 | 203 | 624 | 0 |
| 31 Dec 23 | 1,600 | 172 | 601 | 0 |
| 30 Sep 23 | 1,466 | 150 | 562 | 0 |
| 30 Jun 23 | 1,343 | 149 | 523 | 0 |
| 31 Mar 23 | 1,241 | 123 | 486 | 0 |
| 31 Dec 22 | 1,124 | 118 | 444 | 0 |
| 30 Sep 22 | 1,056 | 118 | 419 | 0 |
| 30 Jun 22 | 1,017 | 107 | 410 | 0 |
| 31 Mar 22 | 967 | 102 | 394 | 0 |
| 31 Dec 21 | 926 | 97 | 385 | 0 |
| 30 Sep 21 | 896 | 76 | 375 | 0 |
| 30 Jun 21 | 869 | 64 | 359 | 0 |
| 31 Mar 21 | 845 | 67 | 339 | 0 |
| 31 Dec 20 | 828 | 63 | 329 | 0 |
| 30 Sep 20 | 802 | 55 | 326 | 0 |
| 30 Jun 20 | 786 | 53 | 317 | 0 |
| 31 Mar 20 | 763 | 47 | 308 | 0 |
| 31 Dec 19 | 757 | 55 | 294 | 0 |
| 30 Sep 19 | 734 | 43 | 288 | 0 |
| 30 Jun 19 | 740 | 41 | 291 | 0 |
| 31 Mar 19 | 727 | 32 | 297 | 0 |
| 31 Dec 18 | 709 | 24 | 298 | 0 |
| 30 Sep 18 | 716 | 14 | 286 | 0 |
| 30 Jun 18 | 689 | 8 | 278 | 0 |
| 31 Mar 18 | 660 | 10 | 268 | 0 |
| 31 Dec 17 | 617 | 7 | 261 | 0 |
| 31 Oct 17 | 779 | 11 | 298 | 0 |
| 31 Jul 17 | 802 | 3 | 301 | 0 |
| 30 Apr 17 | 853 | 0 | 299 | 0 |
| 31 Jan 17 | 901 | 5 | 291 | 0 |
| 31 Oct 16 | 897 | 10 | 276 | 0 |
| 31 Jul 16 | 874 | 19 | 258 | 0 |
| 30 Apr 16 | 818 | 20 | 239 | 0 |
| 31 Jan 16 | 817 | 18 | 232 | 0 |
| 31 Oct 15 | 818 | 17 | 226 | 0 |
| 31 Jul 15 | 825 | 8 | 228 | 0 |
| 30 Apr 15 | 855 | 9 | 228 | 0 |
| 31 Jan 15 | 891 | 9 | 226 | 0 |
| 31 Oct 14 | 913 | 15 | 221 | 0 |
| 31 Jul 14 | 910 | 21 | 213 | 0 |
| 30 Apr 14 | 827 | 23 | 203 | 0 |
| 31 Jan 14 | 651 | 18 | 185 | 0 |
| 31 Oct 13 | 517 | 11 | 176 | 0 |
| 31 Jul 13 | 402 | 17 | 168 | 0 |
Quality Earnings: 61MA has high quality earnings.
Growing Profit Margin: 61MA's current net profit margins (12.1%) are higher than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 61MA's earnings have grown significantly by 32% per year over the past 5 years.
Accelerating Growth: 61MA's earnings growth over the past year (65.6%) exceeds its 5-year average (32% per year).
Earnings vs Industry: 61MA earnings growth over the past year (65.6%) exceeded the Life Sciences industry 1.1%.
Return on Equity
High ROE: 61MA's Return on Equity (18.6%) is considered low.